|Bid||38.90 x 1000|
|Ask||40.47 x 800|
|Day's Range||39.08 - 39.70|
|52 Week Range||32.03 - 43.98|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 16, 2019 - May 20, 2019|
|Forward Dividend & Yield||1.40 (3.89%)|
|1y Target Est||35.69|
Although high input costs are a concern for players in the consumer staples sector, a few are likely to gain from prudent acquisitions, savings and brand augmenting efforts.
Hershey (HSY) is likely to gain from buyouts in Q1. While the company is battling high freight and logistics costs, strategic pricing and Margin for Growth program should be a breather.
Kimberly-Clark's (KMB) Q1 earnings are likely to be hurt by escalated costs and foreign-currency headwinds. However, restructuring plans are likely to offer respite.
Campbell (CPB) inks deal to divest Bolthouse Farms to an affiliate of Butterfly Equity. The deal is expected to conclude by the end of fiscal 2019.
Campbell Soup Co. has sold its healthy food brand Bolthouse Farms to Butterfly, a Los Angeles-based private-equity firm, for $510 million in cash. Campbell Soup announced last year that it was in talks to see the fresh food portion of the business. Campbell Soup bought Bolthouse Farms in 2012 for $1.55 billion. Butterfly Operating Partner Jeff Dunn will become chief executive of Bolthouse Farms. Dunn helped sell Bolthouse to Campbell Soup, and served at Bolthouse's CEO from 2008 to 2012. He led the brand while at Campbell, until leaving in 2016. The transaction is expected to close in the summer. Campbell Soup stock is up 20.6% for the year to date, outpacing the S&P 500 index , which is up nearly 16%.
Butterfly, a Los Angeles-based private equity firm specializing in the food sector, today announced that it has signed a definitive agreement to acquire Bolthouse Farms from Campbell Soup Company (CPB) for $510 million in cash, subject to customary purchase price adjustments. Founded in 1915 and based in Bakersfield, CA and Santa Monica, CA, Bolthouse Farms is a vertically integrated food and beverage company focused on developing, manufacturing and marketing proprietary, high value-added natural, healthy products. The company has leading market positions in fresh carrots and refrigerated premium beverages in the U.S., along with a strong and growing presence in refrigerated salad dressings.
Campbell Soup Company (CPB) announced today that it has signed a definitive agreement for the sale of Bolthouse Farms to an affiliate of Butterfly Equity, a Los Angeles-based private equity firm specializing in the food sector, for $510 million, subject to customary purchase price adjustments. Upon the completion of the sale of Bolthouse Farms, which is expected by the end of fiscal 2019, Campbell will have divested its entire Campbell Fresh division. Campbell recently announced the sale of Garden Fresh Gourmet and the company’s Everett, Washington, refrigerated soup plant.
Campbell Soup Co. is closing in on a deal to sell the Bolthouse Farms fresh-foods brands to a former CEO of the Bolthouse unit for $500 million.
Former Bolthouse Chief Executive Officer Jeff Dunn, who was leading the group of investors, is working with private-equity firm Butterfly Equity and has entered into exclusive talks with the U.S. food company for Campbell's fresh food unit, the Journal said, citing people familiar with the matter. The Journal in a previous version of the report said that Campbell was nearing a deal to sell its fresh food unit, including Bolthouse Farms.
Former Bolthouse Chief Executive Officer Jeff Dunn, who was leading the group of investors, is working with private-equity firm Butterfly Equity and has entered into exclusive talks with the U.S. food company for Campbell's fresh food unit, the Journal said, citing people familiar with the matter. Earlier this year, Campbell said it expects to name buyers for Bolthouse Farms and its international business by the end of fiscal 2019.
Campbell is in advanced talks to sell Bolthouse Farms to an investor group led by former its former CEO Jeffrey Dunn, for roughly $500 million, a person familiar with the talks tells CNBC. Campbell paid $1.55 billion for Bolthouse Farms in 2012. Campbell Soup CPB is nearing a deal to sell Bolthouse Farms to its former CEO for roughly half of what it paid for the carrot and juice company seven years ago, a person familiar tells CNBC.
Campbell Soup Co. is reportedly nearing a deal to sell Bolthouse Farms for $500 million to a group of investors led by the company's former CEO. Camden, N.J.-based Campbell Soup Co. since last year has been looking to divest its international and fresh divisions to focus on Snacks and Campbell Meals and Beverages, the company's core North American market. The company has already sold Garden Fresh Gourmet as well as its refrigerated soup plant in Washington.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Why Credit Suisse Upgraded J.M. Smucker Stock(Continued from Prior Part)Low growth expectations are a concern While the J.M. Smucker Company’s (SJM) recent financial performance has been impressive, the expected slowdown in its sales could limit
Why Credit Suisse Upgraded J.M. Smucker StockJ.M. Smucker upgraded to a “neutral” The J.M. Smucker Company (SJM) stock was up ~1.3% in morning trading on April 8 after Credit Suisse upgraded its rating owing to its improved earnings prospects.
A strong end to a strong week left the S&P 500 at its best weekly close since September. Namely, the close at 2,892.74 was 0.46% better than Thursday's last trade, capping off a 2.0% gain for the five-day span.Snap (NYSE:SNAP) set the pace, gaining nearly 5% during the session's regular hours only to add another 5% in after-hours action as investors celebrated the company's foray into social gaming. RBC upgraded SNAP stock, and raised its price target from $10 to $17. Chesapeake Energy (NYSE:CHK) fared well too, up a little more than 6% during the session, largely driven by ongoing gains in the price of gas and oil.Not all stocks ended Friday in the black, however. Holding the marketwide bullish effort back was Boston Beer Company (NYSE:SAM). Shares of the brewer fell 5.5% in response to a downgrade from Goldman Sachs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHeaded into the new trading week, it's the stock charts of Centurylink (NYSE:CTL), Campbell Soup Company (NYSE:CPB) and Bristol-Myers Squibb (NYSE:BMY) worth the closest technical looks. Here's why. Campbell Soup Company (CPB)Campbell Soup Company has been a miserable performer since the middle of 2016, losing nearly half of its value on a combination of company and industry problems. The last several attempts at a technical turnaround have gotten nowhere. * 10 Medical Marijuana Stocks to Cure Your Portfolio As of Friday, though, the stock has shown the most hope for a new, prolonged uptrend than we've seen in years. A few more good "up" days could do the trick. Click to Enlarge • The defining trigger is the move back above the 200-day moving average line, plotted in white on both stock charts. Past tries have failed to go anywhere, but Friday's was the first time we've seen such a quick re-attempt.• That renewed attempt has taken shape following a potential double-bottom around $32, plotted with a blue dashed line on both stock charts. That's the first time since 2017 we've not made lower lows.• As the weekly chart indicates, slowly but surely Campbell Soup shares are pushing above falling resistance lines. The one in play now, plotted in an aqua color, is the last one to hurdle.• Though encouraging, this reversal -- given the stock's long-lived history -- may be one that takes a few weeks to complete, being more of a process and less of an event. Bristol-Myers Squibb (BMY)It's rare for a blue chip like Bristol-Myers Squibb to slip into a long-term downtrend in the middle of a bull market … rare but not unheard of. Indeed, the one BMY stock has been suffering since mid-2016 has become so well-developed it's taken on a life of its own. Moreover, as overdue as it looks and feels like a bounce may be, one more stumble could drag Bristol-Myers under well-established floor and further accelerate the selling. Click to Enlarge • The floor in question is just above the $46 mark, plotted with a red dashed line on both stock charts. That's near where BMY made a major low in 2014, 2017, a couple of times last year, and last week.• In the meantime, Bristol-Myers Squibb has made increasingly lower lows.• Though the $46 area so far has proven to be support, the selling volume has soared just within the past month. That's a new development, suggesting the sellers are just now starting to crawl out of the woodwork, perhaps fearing the future is grim. Centurylink (CTL)Finally, Centurylink has been shellacked since October, guided lower by a well-defined falling resistance line. The bleeding started to stop in March, however, and as of last week the healing appears to have begun. The effort needs to be a little more solidified, but a lot of bullish clues are starting to become evident. Equally evident is that the bears seem to have overshot their target.The falling resistance line is plotted in yellow on both stock charts. While unable to break above it through February, the sideways action last month was enough to break the ceiling. Click to Enlarge• As of Friday, CTL shares have moved above a horizontal resistance level at 12.50, plotted in red on the daily chart. Better still is Friday's breakthrough gain took shape on above-average bullish volume.• Zooming out to the weekly chart, we can see the RSI indicator broke below the oversold threshold at 30 last month, but more important, pushed back above it last week. That recovery is a key buy signal.• Although the purple 50-day moving average line could prove to be resistance at $13.12, given the scope of the selloff, it's the gray 100-day and white 200-day moving average at $15 and near $18 that are the more plausible technical ceilings.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Data Center Buys That Deliver Sizable Income * 7 High-Risk Stocks With Big Potential Rewards * 3 Marijuana Stocks to Watch as New York, New Jersey Delay Legalization Compare Brokers The post 3 Big Stock Charts for Monday: Bristol-Myers Squibb, Centurylink and Campbell Soup Company appeared first on InvestorPlace.
Mondelez, the lead contender for the sale of Campbell Soup's Arnott's cookie and crackers brands, has reached a stalemate with the packaged soup company, people familiar tell CNBC. The Oreo-owner submitted a final offer that was below Campbell's sale expectations of roughly $3 billion. It is common for there to be last minute negotiations over price in deal talks, and it is possible Mondelez and Campbell find a resolution.
Campbell Soup Co. named a new CEO in December, and it's board chair announced his retirement. There's more C-suite changes in store.
Daniel Loeb's Third Point released its Q4 2018 Investor Letter at the end of February, in which discussed its several 13F positions, including Campbell Soup Company (NYSE:CPB). If you are interested you can download a copy of the letter - here. Campbell Soup Company was the fund's new addition during the second quarter of 2018, […]